195 related articles for article (PubMed ID: 23821768)
1. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study.
Takeuchi H; Suzuki T; Remington G; Bies RR; Abe T; Graff-Guerrero A; Watanabe K; Mimura M; Uchida H
Schizophr Bull; 2013 Sep; 39(5):993-8. PubMed ID: 23821768
[TBL] [Abstract][Full Text] [Related]
2. Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: A single-blinded, 52-week, randomized controlled study.
Zhou Y; Li G; Li D; Cui H; Ning Y
J Psychopharmacol; 2018 May; 32(5):524-532. PubMed ID: 29493377
[TBL] [Abstract][Full Text] [Related]
3. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
Rosa F; Schreiner A; Thomas P; Sherif T
Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
[TBL] [Abstract][Full Text] [Related]
4. Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.
Ganguli R; Brar JS; Mahmoud R; Berry SA; Pandina GJ
BMC Med; 2008 Jun; 6():17. PubMed ID: 18590519
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
[TBL] [Abstract][Full Text] [Related]
6. Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study.
Takeuchi H; Suzuki T; Bies RR; Remington G; Watanabe K; Mimura M; Uchida H
J Clin Psychiatry; 2014 Nov; 75(11):1209-14. PubMed ID: 25099201
[TBL] [Abstract][Full Text] [Related]
7. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
Goff DC; Lamberti JS; Leon AC; Green MF; Miller AL; Patel J; Manschreck T; Freudenreich O; Johnson SA
Neuropsychopharmacology; 2008 Feb; 33(3):465-72. PubMed ID: 17487227
[TBL] [Abstract][Full Text] [Related]
8. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
[TBL] [Abstract][Full Text] [Related]
10. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
Kane JM; D'Souza DC; Patkar AA; Youakim JM; Tiller JM; Yang R; Keefe RS
J Clin Psychiatry; 2010 Nov; 71(11):1475-81. PubMed ID: 20816042
[TBL] [Abstract][Full Text] [Related]
11. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
Keefe RS; Sweeney JA; Gu H; Hamer RM; Perkins DO; McEvoy JP; Lieberman JA
Am J Psychiatry; 2007 Jul; 164(7):1061-71. PubMed ID: 17606658
[TBL] [Abstract][Full Text] [Related]
12. Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia.
Faries DE; Ascher-Svanum H; Nyhuis AW; Kinon BJ
Curr Med Res Opin; 2008 May; 24(5):1399-405. PubMed ID: 18397549
[TBL] [Abstract][Full Text] [Related]
13. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
[TBL] [Abstract][Full Text] [Related]
14. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study.
Harvey PD; Green MF; McGurk SR; Meltzer HY
Psychopharmacology (Berl); 2003 Sep; 169(3-4):404-11. PubMed ID: 12590356
[TBL] [Abstract][Full Text] [Related]
15. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia.
Jeste DV; Barak Y; Madhusoodanan S; Grossman F; Gharabawi G
Am J Geriatr Psychiatry; 2003; 11(6):638-47. PubMed ID: 14609804
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
17. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
[TBL] [Abstract][Full Text] [Related]
19. Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial.
Sakurai H; Suzuki T; Bies RR; Pollock BG; Mimura M; Kapur S; Uchida H
J Clin Psychiatry; 2016 Oct; 77(10):1381-1390. PubMed ID: 27788310
[TBL] [Abstract][Full Text] [Related]
20. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
